NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery

CompletedPhase 2

Sponsor: University College, London

Conditions: Rectal Cancer

Interventions: Bevacizumab, Irinotecan, Oxaliplatin, 5-Fluorouracil

Countries: United Kingdom

The purpose of this study is to evaluate the efficacy, toxicity and feasibility of FOLFOX/ bevacizumab and FOLFOXIRI/ bevacizumab neoadjuvant therapy in poor prognosis rectal cancer as defined by MRI.

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion

* Histologically confirmed diagnosis of adenocarcinoma of the rectum
* Distal part of the tumour within 4-12 cm of the anal verge
* No unequivocal evidence of established metastatic disease (on chest/abdominal/pelvis CT).Patients with equivocal lesions (as determined at MDT) are eligible
* MRI-evaluated locally advanced tumour with the following:
* T3 tumours extending (≥ 4 mm), beyond the muscularis propria N0-N2
* Or tumours (involving or threatening the peritoneal surface)
* OR presence of macroscopic extramural venous invasion (V2 disease)
* AND for tumours below the peritoneal reflection, the primary tumour or involved lymph node (on MRI) must be \>1 mm from the mesorectal fascia
* Measurable disease (using RECIST criteria v1.1)
* WHO performance status 0 - 1
* In the opinion of the investigator:

  * General condition considered suitable for radical pelvic surgery
  * Candidate for systemic therapy with FOLFOX/FOLFOXIRI plus bevacizumab
* Adequate bone marrow, hepatic and renal function:

  * Haemoglobin ≥80 g/L
  * ANC ≥2 x 109/L
  * Platelet count ≥100 x 109/L
  * ALT or AST ≤1.5 x ULN (upper limit of normal)
  * ALP ≤1.5 x ULN
  * Total bilirubin ≤1.5 x ULN
  * Serum creatinine ≤1.5 x ULN
  * Creatinine clearance ≥50 mL/min using the Cockcroft-Gault formula
* INR ≤ 1.1
* Urine protein ≤1+ with dipstick or urine analysis

  \- For proteinuria ≥2+ or urine protein/creatinine ratio ≥ 1.0, 24-h urine protein should be obtained and the level must be ≤2 g for eligibility
* No evidence of established or acute ischaemic heart disease on ECG and normal clinical cardiovascular assessment
* No known significant impairment of intestinal absorption
* At least 18 years of age, but not more than 75 years
* Willing and able to give informed consent, comply with treatment and follow up schedule

Exclusion

* Disease outside of the mesorectal envelope (internal iliac/lateral pelvic lymph node)
* Clinically significant cardiovascular or coronary disease \<2 years before randomisation
* History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan
* History of an arterial thromboembolic event during the previous 2 years
* Evidence of bleeding problems or coagulopathy
* Significant and continuing rectal bleeding leading to a haemoglobin \<8 g/dL
* Patients receiving warfarin/coumarin derived anticoagulants at full therapeutic doses are excluded, but prophylactic doses of 1mg to prevent Hickman line clotting are eligible
* Chronic use of aspirin (\>325 mg/day) or clopidogrel (\>75 mg/day) within 10 days of first planned study treatment
* Require regular use of anti-diarrhoeal (e.g. daily use of loperamide)
* Serious uncontrolled intercurrent illness including poorly controlled diabetes mellitus
* Known hypersensitivity to any of the study drugs
* Serious wound, ulcer or bone fracture
* Current or impending rectal obstruction
* Metallic colonic or rectal stent in situ
* Previous pelvic radiotherapy
* Previous intolerance to fluoropyrimidine chemotherapy
* Previous treatment with bisphosphonates
* Infectious illness requiring antibiotics within 1 week of randomisation
* Previous treatment with another investigational agent within 30 days prior to randomisation
* Patients with a history of previous malignancy in the past 5 years, excepting basocellular or squamous cell skin cancer, or properly treated cervicouterine cancer in situ
* Known HIV, HBV or HCV infection
* Current smoker, or clinically relevant history of drug or alcohol abuse
* Pregnant or lactating women or pre menopausal women not using adequate contraception. Men and women of child-bearing potential must use adequate contraception
* Patients with any other condition or concurrent medical or psychiatric disease who, in the opinion of the investigator, is not eligible to enter the study
* Inability or unwillingness to comply with the protocol

Locations (11)

Blackpool, United Kingdom
Glasgow, United Kingdom
London, United Kingdom
London, United Kingdom
London, United Kingdom
London, United Kingdom
London, United Kingdom
London, United Kingdom
Middlesex, United Kingdom
Slough, United Kingdom
Stevenage, United Kingdom